Proton Pump Inhibitors – PPIs

Supplied:  Capsule (delayed release): 20 mg, 40 mg.  Granules - for oral suspension: 20 mg, 40 mg. Injection (powder for reconstitution): 20 mg, 40 mg.
Dosing:  Healing of erosive esophagitis: Oral: Initial: 20-40 mg once daily for 4-8 weeks. if incomplete healing, may continue for an additional 4-8 weeks. Maintenance: 20 mg once daily.
Symptomatic gastroesophageal reflux: Oral: 20 mg once daily for 4 weeks. 
Peptic ulcer disease: Eradication ofHelicobacter pylori: Oral: 40 mg once daily for 10 days -- requires combination therapy.
Pathological hypersecretory conditions (Zollinger-Ellison syndrome): 40 mg twice daily; adjust regimen to individual patient needs; doses up to 240 mg/day have been administered.

Supplied:  Capsule (delayed release): 15 mg, 30 mg. Granules (for oral suspension): 15 mg and 30 mg packets.  Injection (powder for reconstitution): 30 mg.  Orally disintegrating tablet: 15 mg, 30 mg.
Dosing:  Duodenal ulcer: Oral: Short-term treatment: 15 mg once daily for 4 weeks. Maintenance therapy: 15 mg once daily.  Gastric ulcer: Oral: Short-term treatment: 30 mg once daily for up to 8 weeks.
Symptomatic GERD: Oral: Short-term treatment: 15 mg once daily for up to 8 weeks.
Erosive esophagitis:  Oral: Short-term treatment: 30 mg once daily for up to 8 weeks. Maintenance therapy: 15 mg once daily.     IV: 30 mg once daily for up to 7 days... patients should be switched to an oral formulation as soon as they can take oral medications.
Hypersecretory conditions: Oral: Initial: 60 mg once daily; adjust dose based upon patient response and to reduce acid secretion to <10 mEq/hour (5 mEq/hour in patients with prior gastric surgery). Doses of 90 mg twice daily have been used... administer doses >120 mg/day in divided doses.
Prevention of rebleeding in peptic ulcer bleed: 60 mg IV, followed by 6 mg/hour infusion for 72 hours.

Supplied:  Capsule: 10 mg, 20 mg, 40 mg.  Tablet (OTC): 20 mg
Dosing:  Active duodenal ulcer: Oral: 20 mg/day for 4-8 weeks.
Erosive esophagitis: Oral: 20 mg/day for 4-8 weeks.  Maintenance of healing: 20 mg/day for up to 12 months total therapy.
Gastric ulcers: Oral: 40 mg/day for 4-8 weeks.
Symptomatic GERD: Oral: 20 mg/day for up to 4 weeks.
Pathological hypersecretory conditions: Oral: Initial: 60 mg once daily; doses up to 120 mg 3 times daily have been administered. Administer daily doses >80 mg in divided doses.

Supplied:  Tablet (delayed release):  20 mg, 40 mg.  Injection (powder for reconstitution): 40 mg.
Dosing: Erosive esophagitis associated with GERD:  Oral:  Treatment: 40 mg once daily for up to 8 weeks.  An additional 8 weeks may be used in patients who have not healed after an 8-week course.  Maintenance of healing: 40 mg once daily.   I.V.: 40 mg once daily for 7-10 days.
Hypersecretory disorders (including Zollinger-Ellison): Oral: Initial: 40 mg twice daily. Adjust dose based on patient needs.  Doses up to 240 mg/day have been administered.   IV: 80 mg twice daily. Adjust dose based on acid output measurements.
Prevention of rebleeding in peptic ulcer bleed : IV: 80 mg, followed by 8 mg/hour infusion for 72 hours.

Supplied:  Tablet (delayed release):  20 mg
Dosing:  Duodenal ulcer: Oral: 20 mg/day before breakfast for 4 weeks.
GERD: Oral: 20 mg once daily for 4-8 weeks; maintenance: 20 mg once daily.
Hypersecretory conditions: Oral: 60 mg once daily. Dose may need to be adjusted as necessary. Doses as high as 100 mg once daily and 60 mg twice daily have been used.